1. Home
  2. PUMP vs ANNX Comparison

PUMP vs ANNX Comparison

Compare PUMP & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProPetro Holding Corp.

PUMP

ProPetro Holding Corp.

HOLD

Current Price

$16.87

Market Cap

1.0B

Sector

Energy

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.32

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUMP
ANNX
Founded
2007
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
812.7M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
PUMP
ANNX
Price
$16.87
$5.32
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$14.14
$16.50
AVG Volume (30 Days)
5.5M
1.9M
Earning Date
04-30-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
100.76
N/A
EPS
N/A
N/A
Revenue
$1,269,158,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$15.61
$16,320.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.51
$1.85
52 Week High
$18.50
$7.18

Technical Indicators

Market Signals
Indicator
PUMP
ANNX
Relative Strength Index (RSI) 52.47 44.52
Support Level $14.90 $5.28
Resistance Level N/A $5.61
Average True Range (ATR) 0.89 0.30
MACD -0.04 -0.03
Stochastic Oscillator 50.24 40.34

Price Performance

Historical Comparison
PUMP
ANNX

About PUMP ProPetro Holding Corp.

ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: